vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and Paranovus Entertainment Technology Ltd. (PAVS). Click either name above to swap in a different company.

Paranovus Entertainment Technology Ltd. is the larger business by last-quarter revenue ($12.4M vs $9.5M, roughly 1.3× Cellectis S.A.). Paranovus Entertainment Technology Ltd. runs the higher net margin — -5.5% vs -265.9%, a 260.4% gap on every dollar of revenue. On growth, Paranovus Entertainment Technology Ltd. posted the faster year-over-year revenue change (18033.4% vs 375.0%).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

CLLS vs PAVS — Head-to-Head

Bigger by revenue
PAVS
PAVS
1.3× larger
PAVS
$12.4M
$9.5M
CLLS
Growing faster (revenue YoY)
PAVS
PAVS
+17658.4% gap
PAVS
18033.4%
375.0%
CLLS
Higher net margin
PAVS
PAVS
260.4% more per $
PAVS
-5.5%
-265.9%
CLLS

Income Statement — Q2 FY2024 vs Q2 FY2026

Metric
CLLS
CLLS
PAVS
PAVS
Revenue
$9.5M
$12.4M
Net Profit
$-25.3M
$-681.0K
Gross Margin
20.0%
Operating Margin
-181.1%
-5.1%
Net Margin
-265.9%
-5.5%
Revenue YoY
375.0%
18033.4%
Net Profit YoY
-51.9%
61.4%
EPS (diluted)
$-0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
PAVS
PAVS
Q3 25
$12.4M
Q2 24
$9.5M
Q3 23
$1.6M
$0
Q2 23
$2.0M
Q2 22
$2.7M
Net Profit
CLLS
CLLS
PAVS
PAVS
Q3 25
$-681.0K
Q2 24
$-25.3M
Q3 23
$-17.5M
$8.2M
Q2 23
$-16.6M
Q2 22
$-19.5M
Gross Margin
CLLS
CLLS
PAVS
PAVS
Q3 25
20.0%
Q2 24
Q3 23
Q2 23
97.3%
Q2 22
87.9%
Operating Margin
CLLS
CLLS
PAVS
PAVS
Q3 25
-5.1%
Q2 24
-181.1%
Q3 23
-1258.1%
Q2 23
-1180.5%
Q2 22
-1003.0%
Net Margin
CLLS
CLLS
PAVS
PAVS
Q3 25
-5.5%
Q2 24
-265.9%
Q3 23
-1064.1%
Q2 23
-831.6%
Q2 22
-714.4%
EPS (diluted)
CLLS
CLLS
PAVS
PAVS
Q3 25
Q2 24
$-0.28
Q3 23
$-0.31
Q2 23
$-0.20
Q2 22
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
PAVS
PAVS
Cash + ST InvestmentsLiquidity on hand
$149.0M
$5.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$148.6M
$23.6M
Total Assets
$407.1M
$37.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
PAVS
PAVS
Q3 25
$5.2M
Q2 24
$149.0M
Q3 23
$1.0M
Q2 23
$84.4M
Q2 22
$129.4M
Stockholders' Equity
CLLS
CLLS
PAVS
PAVS
Q3 25
$23.6M
Q2 24
$148.6M
Q3 23
$76.1M
$10.7M
Q2 23
$96.6M
Q2 22
$180.5M
Total Assets
CLLS
CLLS
PAVS
PAVS
Q3 25
$37.3M
Q2 24
$407.1M
Q3 23
$209.7M
$11.2M
Q2 23
$227.7M
Q2 22
$320.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
PAVS
PAVS
Operating Cash FlowLast quarter
$28.9M
$-159.3K
Free Cash FlowOCF − Capex
$27.6M
FCF MarginFCF / Revenue
290.5%
Capex IntensityCapex / Revenue
13.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
PAVS
PAVS
Q3 25
$-159.3K
Q2 24
$28.9M
Q3 23
$-13.1M
Q2 23
$-47.4M
Q2 22
$-60.2M
Free Cash Flow
CLLS
CLLS
PAVS
PAVS
Q3 25
Q2 24
$27.6M
Q3 23
Q2 23
$-47.9M
Q2 22
$-61.7M
FCF Margin
CLLS
CLLS
PAVS
PAVS
Q3 25
Q2 24
290.5%
Q3 23
Q2 23
-2391.4%
Q2 22
-2266.7%
Capex Intensity
CLLS
CLLS
PAVS
PAVS
Q3 25
Q2 24
13.2%
Q3 23
Q2 23
24.1%
Q2 22
56.6%
Cash Conversion
CLLS
CLLS
PAVS
PAVS
Q3 25
Q2 24
Q3 23
-1.60×
Q2 23
Q2 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons